Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.
from WSJ.com: US Business http://ift.tt/2ocZ6Bz
via IFTTT
No comments:
Post a Comment